AU2019397614B2 - Antibodies to human complement factor C2b and methods of use - Google Patents

Antibodies to human complement factor C2b and methods of use Download PDF

Info

Publication number
AU2019397614B2
AU2019397614B2 AU2019397614A AU2019397614A AU2019397614B2 AU 2019397614 B2 AU2019397614 B2 AU 2019397614B2 AU 2019397614 A AU2019397614 A AU 2019397614A AU 2019397614 A AU2019397614 A AU 2019397614A AU 2019397614 B2 AU2019397614 B2 AU 2019397614B2
Authority
AU
Australia
Prior art keywords
ser
val
leu
gly
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019397614A
Other languages
English (en)
Other versions
AU2019397614A1 (en
Inventor
Christophe Blanchetot
Hans De Haard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ArgenX BVBA
Original Assignee
ArgenX BVBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ArgenX BVBA filed Critical ArgenX BVBA
Publication of AU2019397614A1 publication Critical patent/AU2019397614A1/en
Application granted granted Critical
Publication of AU2019397614B2 publication Critical patent/AU2019397614B2/en
Priority to AU2022287637A priority Critical patent/AU2022287637B2/en
Priority to AU2025252632A priority patent/AU2025252632A1/en
Assigned to argenx BV reassignment argenx BV Request to Amend Deed and Register Assignors: ARGENX BVBA
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Devices For Post-Treatments, Processing, Supply, Discharge, And Other Processes (AREA)
AU2019397614A 2018-12-13 2019-12-13 Antibodies to human complement factor C2b and methods of use Active AU2019397614B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2022287637A AU2022287637B2 (en) 2018-12-13 2022-12-15 Antibodies to human complement factor C2b and methods of use
AU2025252632A AU2025252632A1 (en) 2018-12-13 2025-10-17 Antibodies to human complement factor C2b and methods of use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862779102P 2018-12-13 2018-12-13
US62/779,102 2018-12-13
PCT/IB2019/060802 WO2020121282A1 (en) 2018-12-13 2019-12-13 Antibodies to human complement factor c2b and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022287637A Division AU2022287637B2 (en) 2018-12-13 2022-12-15 Antibodies to human complement factor C2b and methods of use

Publications (2)

Publication Number Publication Date
AU2019397614A1 AU2019397614A1 (en) 2021-06-03
AU2019397614B2 true AU2019397614B2 (en) 2022-09-15

Family

ID=69143627

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2019397614A Active AU2019397614B2 (en) 2018-12-13 2019-12-13 Antibodies to human complement factor C2b and methods of use
AU2022287637A Active AU2022287637B2 (en) 2018-12-13 2022-12-15 Antibodies to human complement factor C2b and methods of use
AU2025252632A Pending AU2025252632A1 (en) 2018-12-13 2025-10-17 Antibodies to human complement factor C2b and methods of use

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2022287637A Active AU2022287637B2 (en) 2018-12-13 2022-12-15 Antibodies to human complement factor C2b and methods of use
AU2025252632A Pending AU2025252632A1 (en) 2018-12-13 2025-10-17 Antibodies to human complement factor C2b and methods of use

Country Status (21)

Country Link
US (4) US11161900B2 (enExample)
EP (2) EP4375297A3 (enExample)
JP (3) JP7110491B2 (enExample)
KR (2) KR102774146B1 (enExample)
CN (2) CN113260375B (enExample)
AU (3) AU2019397614B2 (enExample)
BR (1) BR112021011107A2 (enExample)
CA (1) CA3119655A1 (enExample)
DK (1) DK3893924T3 (enExample)
EA (1) EA202191658A1 (enExample)
ES (1) ES2991894T3 (enExample)
FI (1) FI3893924T3 (enExample)
HU (1) HUE068993T2 (enExample)
IL (2) IL319975A (enExample)
LT (1) LT3893924T (enExample)
MX (2) MX2021006864A (enExample)
PL (1) PL3893924T3 (enExample)
PT (1) PT3893924T (enExample)
SG (1) SG11202105195PA (enExample)
WO (1) WO2020121282A1 (enExample)
ZA (1) ZA202407097B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3893924T3 (pl) * 2018-12-13 2025-01-13 argenx BV Przeciwciała przeciwko ludzkiemu czynnikowi c2b dopełniacza i sposoby zastosowania
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
GB202407051D0 (en) 2024-05-17 2024-07-03 argenx BV Methods of treating osteoarthritis pain
WO2025257157A1 (en) 2024-06-10 2025-12-18 argenx BV Treatment or prevention of ischemia reperfusion injury in organ tranplantation
WO2025260123A1 (en) * 2024-06-17 2025-12-26 CSL Innovation Pty Ltd Anti-c2 antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014189378A1 (en) * 2013-05-23 2014-11-27 Broteio Pharma B.V. Binding molecules that bind human complement factor c2 and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6998468B2 (en) * 2000-03-23 2006-02-14 Tanox, Inc. Anti-C2/C2a inhibitors of complement activation
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
BRPI0908312A2 (pt) 2008-05-05 2015-08-18 Novimmune Sa '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular''
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010056399A1 (en) 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
BR112012033119A2 (pt) * 2010-06-22 2016-10-25 Univ Colorado Regents anticorpos para o fragamento c3d do componente do complemento 3.
US9206257B2 (en) * 2011-04-19 2015-12-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
HUE049154T2 (hu) * 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
PL2753636T3 (pl) 2011-09-07 2020-05-18 The Trustees Of The University Of Pennsylvania Analogi kompstatyny o ulepszonych właściwościach farmakokinetycznych
WO2014096958A1 (en) 2012-11-02 2014-06-26 Academisch Medisch Centrum Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders
ES2912396T3 (es) * 2012-11-02 2022-05-25 Bioverativ Usa Inc Anticuerpos anti-C1s del complemento y uso de los mismos
EP2997045A4 (en) 2013-05-15 2016-11-23 Annexon Inc ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF
CA2859114A1 (en) 2013-08-29 2015-02-28 International Automotive Components Group North America, Inc. Formed articles comprising carbon and natural fibers, methods of manufacture and use thereof
SG11201602522VA (en) 2013-10-02 2016-04-28 Medimmune Llc Neutralizing anti-influenza a antibodies and uses thereof
RS61351B1 (sr) * 2013-10-17 2021-02-26 Omeros Corp Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2
WO2015089368A2 (en) 2013-12-12 2015-06-18 Alnylam Pharmaceuticals, Inc. Complement component irna compositions and methods of use thereof
PL3215527T3 (pl) 2014-11-05 2025-04-28 Annexon, Inc. Humanizowane przeciwciała przeciwko czynnikowi dopełniacza C1Q i ich zastosowanie
AU2016355206A1 (en) * 2015-11-19 2018-05-24 Abbvie Stemcentrx Llc Novel anti-EMR2 antibodies and methods of use
FI3380518T3 (fi) 2015-11-24 2026-05-29 Annexon Inc Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä
MA53248A (fr) * 2016-01-25 2022-02-16 Takeda Pharmaceuticals Co Anticorps anti-c5 à commutation ph améliorée
RU2018130525A (ru) 2016-01-27 2020-02-27 Цсл Беринг Ленгнау Аг РЕКОМБИНАНТНЫЕ Fc-МУЛЬТИМЕРЫ IgG
WO2017196960A1 (en) 2016-05-10 2017-11-16 Annexon, Inc. Anti-complement factor c4/c4b antibodies and uses thereof
WO2018107109A1 (en) * 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Novel anti-kremen2 antibodies and methods of use
SG11201907583TA (en) 2017-03-14 2019-09-27 Bioverativ Usa Inc Methods for treating complement-mediated diseases and disorders
WO2018193427A1 (en) * 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
CA3078971A1 (en) 2017-11-01 2019-05-09 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
PL3893924T3 (pl) 2018-12-13 2025-01-13 argenx BV Przeciwciała przeciwko ludzkiemu czynnikowi c2b dopełniacza i sposoby zastosowania
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014189378A1 (en) * 2013-05-23 2014-11-27 Broteio Pharma B.V. Binding molecules that bind human complement factor c2 and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Rabia et al., "Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility", Biochemical Engineering Journal, vol. 137, pp. 365-374, Jun. 5, 2018. *
Wu et al., "Structure-based engineering of a monoclonal antibody for improved solubility", Protein Engineering, Design and Selection, vol. 23, No. 8, pp. 643-651, Jun. 11, 2010. *

Also Published As

Publication number Publication date
HUE068993T2 (hu) 2025-02-28
IL319975A (en) 2025-05-01
JP7611191B2 (ja) 2025-01-09
KR102774146B1 (ko) 2025-02-26
JP7110491B2 (ja) 2022-08-01
JP2022160479A (ja) 2022-10-19
PT3893924T (pt) 2024-10-09
IL283916B1 (en) 2025-05-01
US11708403B2 (en) 2023-07-25
JP2024160274A (ja) 2024-11-13
US20220119509A1 (en) 2022-04-21
AU2022287637B2 (en) 2025-07-17
IL283916B2 (en) 2025-09-01
IL283916A (en) 2021-07-29
AU2019397614A1 (en) 2021-06-03
ZA202407097B (en) 2026-04-29
MX2021006864A (es) 2021-07-02
AU2025252632A1 (en) 2025-11-06
ES2991894T3 (es) 2024-12-05
SG11202105195PA (en) 2021-06-29
US11591386B2 (en) 2023-02-28
MX2025010337A (es) 2025-10-01
DK3893924T3 (da) 2024-11-04
PL3893924T3 (pl) 2025-01-13
BR112021011107A2 (pt) 2021-12-14
US20220267424A1 (en) 2022-08-25
NZ776117A (en) 2024-07-26
EA202191658A1 (ru) 2021-11-03
AU2022287637A1 (en) 2023-02-02
EP4375297A3 (en) 2024-10-30
US11161900B2 (en) 2021-11-02
EP3893924B1 (en) 2024-08-21
EP3893924A1 (en) 2021-10-20
CN119371526A (zh) 2025-01-28
EP4375297A2 (en) 2024-05-29
KR20210100688A (ko) 2021-08-17
WO2020121282A1 (en) 2020-06-18
KR20250030005A (ko) 2025-03-05
LT3893924T (lt) 2024-10-10
JP2022512223A (ja) 2022-02-02
CN113260375B (zh) 2024-10-01
FI3893924T3 (fi) 2024-10-04
US20240002484A1 (en) 2024-01-04
CN113260375A (zh) 2021-08-13
US20200239554A1 (en) 2020-07-30
CA3119655A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
US11053306B2 (en) Fusion protein constructs comprising anti-C3d antibody and factor H
KR102774146B1 (ko) 인간 보체 인자 c2b 에 대한 항체 및 이의 사용방법
HK40121588A (en) Antibodies to human complement factor c2b and methods of use
CA3123004C (en) Fusion protein constructs for complement associated disease
HK40104765A (en) Antibodies to human complement factor c2b and methods of use
HK40050349B (en) Antibodies to human complement factor c2b and methods of use
HK40051472B (en) Antibodies to human complement factor c2b and methods of use
HK40051472A (en) Antibodies to human complement factor c2b and methods of use
EA052525B1 (ru) Антитела против фактора c2b комплемента человека и способы применения
EA046598B1 (ru) Антитела против фактора c2b комплемента человека и способы применения
HK40050349A (en) Antibodies to human complement factor c2b and methods of use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: ARGENX BV

Free format text: FORMER NAME(S): ARGENX BVBA